In metastatic cancer, these pathways are activated by pro-inflammatory cytokines such as interleukin 6 (IL-6), interleukin 1 (IL-1), tumor necrosis factor alpha (TNF-α), and interferon gamma (IFN-γ) [17–20]. This evidence concerns the gene IL6 and metastatic malignant neoplasm.